Alligator Bioscience AB: Year-end Report January-December 2020

On February 26, 2021 Alligator Bioscience reported Safety data has been presented from the ongoing Phase I study with ATOR-1017 in patients with metastatic cancer (Press release, Alligator Bioscience, FEB 26, 2021, View Source [SID1234575783]). The results show a promising safety profile with only minor drug-related side effects."
– Per Norlén, CEO Alligator Bioscience

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

SIGNIFICANT EVENTS OCTOBER-DECEMBER

Mitazalimab:

New preclinical comparative data showed that mitazalimab has highly competitive immunostimulatory characteristics.
IND approved for forthcoming clinical studies in the US.
CTA submitted for launch of the forthcoming Phase II study in pancreatic cancer.
ATOR-1017:

Predicted therapeutic range dose levels reached in ongoing Phase I study.
Data Review Committee approved start of dosing at 200 mg, corresponding to approximately 3 mg/kg.
ALG.APV-527:

Alligator Bioscience and Aptevo Therapeutics commenced preparations for start of Phase I.
Other:

ALLIGATOR-FAB antibody library launched.
SIGNIFICANT EVENTS AFTER THE END OF THE PERIOD

Oversubscribed rights issue generated proceeds of SEK 86 million before transaction costs.
FINANCIAL SUMMARY

October-December 2020

Net sales, SEK 0.0 million (0.0).
Operating result, SEK -34.1 million (-59.3).
Result for the period, SEK -34.5 million (-59.8).
Earnings per share before and after dilution, SEK -0.48 (-0.84).
Cash flow for the period, SEK -33.2 million (8.6).
Cash and cash equivalents, incl. interest-bearing securities, SEK 103.3 million (249.9).
January-December 2020

Net sales, SEK 4.4 million (4.4).
Operating result, SEK -144.3 million (-214.5).
Result for the period, SEK -143.3 million (-210.1).
Earnings per share before and after dilution, SEK -2.01 (-2.94).
Cash flow for the period, SEK 9.4 million (-19.6).
During the first quarter, the holdings in corporate bonds and interest funds were divested, which had a positive effect on cash flow.

The full report is attached as PDF available on the company’s website: View Source

Conference call/webcast
Alligator will host a conference call today, February 26, 2021, at 2:00 p.m. CEST for investors, analysts and media, where CEO Per Norlén and CFO Marie Svensson will present and comment on the Year-end Report. The conference will be held in English.